To the authors' knowledge, there is limited information regarding the long-term risk of congestive heart failure (CHF) among patients with follicular lymphoma, a prevalent non-Hodgkin lymphoma diagnosis among those aged >65 years, especially within the context of therapeutic exposures and preexisting comorbidities. METHODS: Using Surveillance, Epidemiology, and End Results-Medicare data from 1999 through 2013, the authors identified 6109 patients with follicular lymphoma who were diagnosed at age ≥66 years between January 1, 2000 and December 31, 2011, and a frequency-matched Medicare noncancer sample. Subdistribution hazards models assessed risks associated with new-onset CHF through December 31, 2013. Propensity scorematched models examined CHF risk in patients receiving anthracyclines when compared with matched noncancer controls. RESULTS: When compared with matched controls, patients with follicular lymphoma receiving anthracyclines at ages 66 to 75 years had a 1.7-fold (95% confidence interval, 1.4-fold to 2.1-fold) higher risk of new-onset CHF; patients diagnosed at age >75 years did not differ from noncancer controls with regard to CHF risk. Preexisting hypertension was associated with a 1.7-fold and 1.35-fold, respectively, increased hazard of CHF for each age group, independent of anthracycline exposure. Preexisting diabetes was associated with 1.5-fold increased hazard of CHF only in those patients aged 66 to 75 years. Patients with new-onset CHF had a 18% lower 10-year survival compared with those without CHF. CONCLUSIONS: Patients with follicular lymphoma who were exposed to anthracyclines between the ages of 66 years and 75 years were found to be at an increased risk of new-onset CHF; preexisting hypertension and diabetes appeared to increase this risk. The findings of the current study support and inform the risk-based follow-up of vulnerable populations. Cancer 2018;124:4221-4230.
INTRODUCTION
Low-grade lymphomas such as follicular lymphoma constitute approximately 26% of non-Hodgkin lymphoma (NHL) diagnoses, and the majority of patients are diagnosed at age ≥60 years. 1 Successful therapeutic strategies have resulted in a median survival of >10 years. 2 Unfortunately, therapeutic exposures responsible for long-term survival also are implicated in long-term sequelae among survivors. 3 A highly effective therapeutic regimen for the treatment of patients with advanced follicular lymphoma includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with or without radiotherapy. 4, 5 This anthracycline-containing chemotherapy regimen can increase the risk of congestive heart failure (CHF) 6, 7 ; exposure to chest radiation and preexisting comorbidities may increase this risk further. However, to the best of our knowledge, available studies in survivors of NHL have focused on nonelderly populations, with limited follow-up after diagnosis or small samples, or are based exclusively on patients with aggressive lymphoma (primarily diffuse large B-cell lymphoma). [8] [9] [10] [11] [12] [13] Given that the median age at the time of diagnosis of follicular lymphoma is 65 years, it is critical to understand the contribution of therapeutic exposures to CHF risk among older patients and to examine the moderating effect of preexisting comorbidities on the relationship between therapeutic exposures and CHF.
Understanding the risk of new-onset CHF in older adults with follicular lymphoma and evaluating the contribution of potentially cardiotoxic therapeutic exposures is critical to informing long-term risk-based survivorship care. We used population-based data from the Surveillance, Epidemiology, and End Results (SEER) program linked with Medicare administrative claims to address these gaps.
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MATERIALS AND METHODS

Population
Patients with cancer
We used SEER data to identify individuals aged ≥66 years (allowing for a minimum of 1 year of prediagnosis claims) with incident follicular lymphoma (6109 patients) who were diagnosed between January 1, 2000 and December 31, 2011. Histological details are provided in Supporting Table 1 . The evaluation period for Medicare claims extended from 1999 to 2013 to ensure our ability to capture precancer morbidity for at least 1 year before diagnosis and the development of CHF for at least 2 years after diagnosis. Individuals enrolled in another managed care or insurance organization in which claims were not captured by Medicare or those who were lacking Part A or B coverage at any point during the eligibility period were excluded to ensure our ability to capture all health care used by the cohort.
Matched noncancer controls
Approximately 5% of the noncancer sample of Medicare beneficiaries residing in the SEER catchment areas were selected randomly to serve as controls for the patients with lymphoma. Again, individuals enrolled in another managed care plan or those who were lacking Part A or B coverage were excluded. Pseudodiagnosis dates were assigned based on the frequency distribution of time since Medicare enrollment to diagnosis for patients with lymphoma. Noncancer controls were selected randomly (without replacement) to frequency-match the categories of age at the time of diagnosis (age 66-70 years,71-75 years,76-80 years, and ≥80 years), sex, Medicare coverage, race, and Charlson Comorbidity Index (CCI) (0, 1, and ≥2 conditions).
Outcome Measures
New-onset morbidity CHF was identified using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes (see Supporting Table 1 ). The CHF diagnosis code could appear anywhere within the first 10 diagnoses codes on the claim. Incident CHF claims after a diagnosis of lymphoma were captured and had to be coupled with the absence of a diagnosis of CHF or cardiovascular disease (stroke/myocardial infarction) (as identified by any inpatient claim or ≥2 outpatient claims) in the year prior to the diagnosis of lymphoma. A categorical variable was created indicating whether the patient's incident CHF claim was: 1) a new-onset inpatient CHF diagnosis; 2) a new-onset outpatient diagnosis of CHF and no inpatient diagnosis; or 3) no CHF diagnosis. The primary outcome was new-onset inpatient claims for CHF after a diagnosis of lymphoma.
Covariate Measures
Lymphoma stage
Stage of disease at the time of diagnosis was determined from SEER using Ann Arbor staging.
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Therapeutic exposures
Details regarding radiotherapy were drawn from SEER and Medicare claims (ICD-9-CM procedural codes in the outpatient or carrier files). The site of radiotherapy was assumed to correspond to the lymphoma diagnosis site and was coded as head and neck, thoracic/axillary, abdominal/pelvic, or other/multiple sites. Chemotherapy details were drawn from outpatient claims, physician carrier claims, inpatient claims, durable medical equipment Medicare claims, and Part D data (years 2007-2013; see Supporting Table 1 ). Chemotherapy was categorized as no chemotherapy, rituximab monotherapy, anthracyclines, and non-anthracycline-containing regimens.
Preexisting comorbidity
Comorbidity was measured using the CCI 15, 16 and hypertension 17 diagnosed within the 12 months before the lymphoma diagnosis. We focused a priori on the role of preexisting (ie, before the diagnosis of lymphoma) hypertension and diabetes (with or without sequelae) in the development of new-onset CHF. Accordingly, we removed diabetes from the overall CCI score to prevent overlap. The remaining comorbidities in the CCI (chronic renal failure, peripheral vascular disease, chronic obstructive pulmonary disease, liver disease, dementia, paralysis, ulcers, and acquired immune deficiency syndrome [AIDS]) were combined into an "other" category and examined as such.
Race/ethnicity
For the analyses restricted to the lymphoma cohort, race/ ethnicity was identified from SEER and patients were categorized as non-Hispanic white, Hispanic, non-Hispanic African American, and Asian American/Pacific Islander. The SEER race/ethnicity classification was not available for the noncancer population, and therefore in the analyses comparing patients with lymphoma with the noncancer cohort, race was derived from Medicare claims; herein, individuals were classified as white, black, Hispanic, and Asian.
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Socioeconomic status
In the analysis restricted to the lymphoma cohort, a census tract-level poverty indicator based on residential address at the time of diagnosis available from SEER was used. The variable categorizes the percentage of the population in the census tract who are living below the poverty level at the time of the lymphoma diagnosis (0%-5%, 5%-10%, 10%-20%, or 20%-100%). In the analyses comparing patients with lymphoma with the noncancer cohort, we constructed a dichotomous variable (yes/no) representing whether or not the beneficiary ever had state buy-in coverage to serve as a proxy measure of socioeconomic status for both the lymphoma and noncancer populations. Individuals with state buy-in coverage included those eligible for Medicaid and other low-income populations.
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Cardiovascular Screening
Among patients with lymphoma who were identified with a diagnosis of new-onset CHF, cardiac screening with echocardiography or multigated acquisition scan was evaluated from the time of the lymphoma diagnosis to 6 months prior to the diagnosis of CHF.
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Statistical Analysis
Lymphoma cohort compared with a noncancer population
We determined the risk of CHF in anthracycline-exposed patients with lymphoma when compared with a propensity score-matched noncancer control group (from the control population) to estimate the average treatment effect. 20 Covariates used to estimate the propensity score included age, race, sex, state buy-in insurance coverage (Medicaid dual eligibility), hypertension, diabetes, and "other" comorbidities (categorized as 0 vs ≥1 of the following conditions: chronic renal failure, peripheral vascular disease, chronic obstructive pulmonary disease, liver disease, dementia, paralysis, ulcers, and AIDS). We evaluated covariate balance between the groups using standardized difference scores before and after matching (see Supporting Table 2 ). 21 When balance was achieved, a one-to-one matching algorithm was used to match the anthracycline-exposed lymphoma group with the noncancer group with a maximum propensity score distance of 0.01. 22 Cumulative incidence functions were used to assess the development of new-onset CHF, censoring for death and outpatient-only CHF diagnosis. We estimated the relative change in the hazard by regressing the risk of developing new-onset CHF on cancer status (patient with cancer receiving anthracyclines vs a noncancer control) in a Cox proportional hazards model without further adjustment. A robust variance estimator was used to account for the matched sets.
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Analyses restricted to the lymphoma population
To examine the risk factors associated with CHF, we used a proportional subdistribution hazards model. 24 Our primary outcome was new-onset inpatient CHF, treating death and those patients with outpatient CHF claims as competing events. Risk factors included age and stage of disease at the time of the lymphoma diagnosis, sex, socioeconomic status, race/ethnicity, chest radiotherapy, chemotherapy (none, rituximab alone, anthracycline-based regimens, and non-anthracycline-based regimens), and preexisting comorbidity (hypertension, diabetes, and other). The following interactions were evaluated: chemotherapy*preexisting hypertension, chemotherapy*preexisting diabetes, chest radiation*preexisting hypertension, and chest radiation*preexisting diabetes. The proportional hazards assumption was assessed by evaluating the weighted Schoenfeld-type residuals for all variables. We identified violations of proportional hazards across age groups and all models were stratified into 2 age categories: 66 to 75 years and >75 years.
Cardiovascular screening
The median total number of cardiac screenings and the median number of screenings per year were estimated overall and for the anthracycline group and nonanthracycline chemotherapy group. Screening also was evaluated based on whether the CHF diagnosis was made in an inpatient versus outpatient setting, using the site of diagnosis as a proxy for the severity of disease. Statistical significance was evaluated using a 2-sample median test.
Survival time
We examined the 10-year survival of patients with follicular lymphoma with and without new-onset inpatient CHF using stratified Kaplan-Meier curves to examine overall survival with log-rank tests to determine statistical significance between groups. We further evaluated the all-cause and cardiovascular-specific mortality by inpatient and outpatient CHF diagnoses to determine the association between the severity of the diagnosis and mortality. CHF was treated as a time-varying covariate. We used SAS statistical software (version 9.4; SAS Institute Inc, Cary, North Carolina). 25 Two-sided P values set at <.01 were considered statistically significant. The current study was approved by the institutional review board at the University of Alabama at Birmingham.
RESULTS
Cohort Characteristics
Patients with follicular lymphoma
The median age at the time of the lymphoma diagnosis was 76 years (range, 66-102 years), and the median length of follow-up was 5 years (range, 0-14 years). Among patients for whom data regarding Ann Arbor stage were available (89.9%), approximately 61% presented with stage III/IV disease. The majority of patients (53.7%) received chemotherapy alone, 6.7% received radiotherapy alone, and 21.9% received both chemotherapy and radiotherapy. The most prevalent chemotherapeutic exposures included anthracycline-containing regimens (30.5%) and rituximab alone (19%). Preexisting hypertension and diabetes were present in 78% and 19%, respectively, of the patients (Table 1) .
Noncancer controls
The median age of the control population at the assigned diagnosis date was 76 years. There were no statistically significant differences noted between the lymphoma and the noncancer cohorts with respect to age, race, sex, or CCI. The median time between the date of diagnosis (for the patients with lymphoma)/pseudodiagnosis date (for the noncancer controls) and the censor date was comparable ( Table 1) .
Risk of CHF: Lymphoma Cohort Compared With the Noncancer Cohort
Anthracycline-exposed patients with follicular lymphoma were found to have a significantly higher incidence of CHF when compared with matched controls (37.7% vs 29.6%; P<.001) (Fig. 1A) , resulting in a 1.37-fold increased risk of new-onset CHF (95% confidence interval [95% CI], 1.19-fold to 1.57-fold). The increased hazard of CHF was observed primarily among those who were aged 66 to 75 years at the time of diagnosis of lymphoma (hazard ratio [HR], 1.71; 95% CI, 1.40-2.08) (Fig. 1B) . There was no significant difference in the CHF risk noted for those diagnosed at age >75 years compared with noncancer controls (HR, 1.08; 95% CI, 0.84-1.27) (Fig. 1C) .
Analyses Restricted to Patients With Lymphoma
In the multivariable model (Table 2) , anthracyclinecontaining regimens were associated with a 2-fold increased hazard of new-onset CHF (95% CI, 1.48-fold to 2.74-fold) among patients aged 66 to 75 years. There was no significant association among those aged >75 years. Non-anthracycline-containing regimens were associated with a 1.7-fold increased hazard of CHF among those individuals aged 66 to 75 years (95% CI, 1.25-fold to 2.40-fold), and a 1.25-fold increased hazard of CHF among those aged >75 years (95% CI, 1.04-fold to 1.52-fold). Preexisting hypertension was associated with an increased hazard of CHF for both age groups, and preexisting diabetes was associated with an increased hazard of CHF among those aged 66 to 75 years. Interaction terms between chemotherapy and diabetes or hypertension were not significant. 
Cardiovascular Screening
Cardiovascular screening was performed in approximately 11% of the lymphoma cohort. The median number of screenings for the anthracycline-exposed versus the non-anthracycline-exposed groups was 3 versus 0 screenings, respectively (P<.001) (see Supporting  Table 3 ). Among anthracycline-exposed patients, the median number of screenings was 0 compared with 1 for those with an inpatient versus outpatient diagnosis of CHF.
Cardiovascular and All-Cause Mortality in the Lymphoma Cohort
Patients with follicular lymphoma who were diagnosed with CHF had a statistically significantly lower 10-year survival rate compared with those patients without CHF (18.0% vs 44.9%; P<.001) (Fig. 2A) . These survival differences were present in both age groups (Figs. 2B and C). As shown in Figure 3 A, in any given year, if an individual had an incident inpatient CHF claim, the subsequent all-cause mortality rate was 2.04-fold greater than if they did not develop CHF (95% CI, 1.86-fold to 2.22-fold). For outpatient-only CHF diagnoses, the risk was 1.48-fold higher for all-cause mortality (95% CI, 1.34-fold to 1.64-fold). In any given year, if an individual had an incident inpatient CHF claim, the subsequent cardiovascular-specific mortality was 3.4-fold greater than if they did not develop CHF (95% CI, 2.76-fold to 4.23-fold) (Fig. 3B) . For outpatient-only diagnoses of CHF, the risk was 1.91-fold higher for cardiovascular-specific mortality (95% CI, 1.51-fold to 2.42-fold). Cancer November 1, 2018 Abbreviations: 95% CI, 95% confidence interval; CHF, congestive heart failure; HR, hazard ratio; RT, radiotherapy. a In addition to the variables shown herein, the models were adjusted for stage of disease at the time of diagnosis. No statistically significant differences were noted. b Subdistribution hazards. c Included chronic renal failure, peripheral vascular disease, liver disease, chronic obstructive pulmonary disease, rheumatoid arthritis, gastric ulcers, paralysis, and acquired immune deficiency syndrome.
Cancer November 1, 2018 DISCUSSION Among the 6109 Medicare beneficiaries diagnosed with follicular lymphoma, those diagnosed between the ages of 66 years and 75 years and exposed to anthracyclinecontaining regimens were found to have an 1.7-fold increased risk of developing new-onset CHF compared with a propensity score-matched noncancer cohort. For those aged >75 years at the time of the lymphoma diagnosis and exposed to anthracyclines, the risk of CHF was similar to that for a noncancer population. When examining the risk factors present among patients with lymphoma, preexisting hypertension was found to increase the risk of developing CHF, regardless of age at the time of diagnosis. Conversely, preexisting diabetes increased the risk of developing CHF among those aged 66 years to 75 years. Furthermore, new-onset CHF in patients with follicular lymphoma was associated with a significantly higher risk of all-cause mortality as well as cardiovascular-related death, with the mortality risk being higher among those diagnosed with CHF in an inpatient setting. Previous studies have demonstrated an increased risk of anthracycline-related CHF in survivors of childhood cancer 26 ; survivors of adult-onset cancer 27 ; survivors of breast cancer 28 ; survivors of Hodgkin lymphoma 29, 30 ; and, most recently, in survivors of aggressive NHL. 13 We found that the increased risk associated with anthracyclines was confined to patients with follicular lymphoma who were diagnosed between the ages of 66 years and 75 years, such that anthracycline-exposed patients were at a 2.0-fold increased risk compared with those not receiving chemotherapy.
In the analysis adjusted for demographics, therapeutic exposures, and preexisting comorbidities, patients with follicular lymphoma with preexisting hypertension were found to be at a 73% and 68% increased risk, respectively, of CHF for those aged 66 years to 75 years and those aged ≥75 years when compared with those without hypertension. Conversely, among patients with follicular lymphoma with preexisting diabetes, the risk was increased by 47% when compared with those without diabetes, but only among those diagnosed with lymphoma between ages 66 years and 75 years. Previous studies conducted among those aged >65 years who were diagnosed with diffuse large B-cell lymphoma, 31, 32 adult survivors of childhood cancer, 26 and those treated with hematopoietic stem cell transplantation have demonstrated a similar increase in the risk of CHF among those with preexisting diabetes or hypertension. 22 These findings inform surveillance strategies for older adults to mitigate the risk of CHF, and also provide evidence of the need to manage diabetes and hypertension aggressively among those at risk of new-onset CHF.
The current study examined cardiac screening practices by anthracycline exposure and, among anthracycline-exposed individuals, by the severity of CHF among patients with follicular lymphoma. The intensity of cardiac screening after a lymphoma diagnosis was found to be higher among anthracycline-exposed versus non-anthracycline-exposed patients with lymphoma. Furthermore, the intensity of cardiac screening was higher for those diagnosed with outpatient CHF versus those diagnosed with inpatient CHF. These findings suggest that the level of cardiac screening among anthracycline-exposed patients with lymphoma is appropriately higher than among those not exposed to anthracyclines. More important, these findings suggest that undergoing some cardiovascular screening could have resulted in the earlier detection of CHF (presenting in the outpatient setting). 27 However, these findings need to be placed within the context of the retrospective nature of this observational study.
We identified an association between non-anthracycline-containing regimens and new-onset CHF for patients with follicular lymphoma, primarily among those diagnosed between the ages of 66 years and 75 years. We speculate that the decision to treat patients with nonanthracycline-containing regimens could have stemmed from the presence of subclinical heart disease at the time of the cancer diagnosis (which was unmeasurable using our methodology), presenting as an association between non-anthracycline-containing regimens and new-onset CHF. Additional sensitivity analyses demonstrated that the nonanthracycline chemotherapy group had greater comorbidity compared with anthracycline group (see Supporting Table 4 ), thereby supporting our hypothesis. It is important to note that rituximab monotherapy and chest radiotherapy were not found to be associated with an increased risk in patients with follicular lymphoma who were diagnosed in either age group. The number of patients receiving chest radiotherapy to the thoracic region was relatively small (63 patients), which may have contributed to the lack of an association.
Several limitations of the current study are important to consider. Health care claims are proxy measures, and claims for comorbidities may underestimate the health status of patients without health care access. 33 Furthermore, we used a proxy measure to estimate the site of radiotherapy based on disease site, and we were unable to examine the dose-response relationship with specific treatments. We also were unable to examine the contribution of lifestyle exposures (smoking, physical activity) to the risk of CHF, which likely biases our estimates toward the null. Additional limitations to the current data set include information regarding the "aggressiveness" and/or progression of lymphoma, the exclusion of "nonspecified lymphoma subtypes" from the analyses (see Supporting Fig. 1) , and a lack of granularity for cause of death when examining cardiovascular-related death. Cancer November 1, 2018 Finally, matching between anthracycline-treated patients with lymphoma and noncancer controls is not an ideal comparison. However, in the real world, patients with lymphoma receive anthracyclines if they do not have excessive comorbidities, subclinical heart disease, or other age-related frailty factors. This was consistent with the findings of the current study, in which patients with lymphoma who did not receive anthracyclines were significantly older and had a greater number of comorbidities. The presented matching precludes statistically separating the contribution of lymphoma as a disease versus the contribution of anthracyclines. However, to the best of our knowledge, there is no biological evidence suggesting that lymphoma causes delayed-onset CHF, whereas there is ample evidence from other cancers that anthracyclines are associated with heart failure. The comparison between anthracycline-exposed patients with lymphoma and the noncancer group is hypothesis generating and the results need to be validated.
These limitations notwithstanding, the current study has several strengths. To our knowledge, this is the first study to describe the magnitude of CHF risk among patients with follicular lymphoma diagnosed in the elderly age range and compared with a matched noncancer population. 3 In an effort to ensure a rigorous definition of CHF, we specified that an inpatient claim for CHF was required to indicate a "new-onset CHF diagnosis" for our primary outcome. Nonetheless, we captured outpatient diagnoses and included them as a competing event if there was no inpatient claim. This distinction of identifying new-onset CHF events based on inpatient diagnostic criteria identifies events of greater severity compared with diagnoses based on outpatient-only diagnoses, thus reducing the risk of misclassification. 33 We found a significantly increased risk of CHF among patients with follicular lymphoma who were treated with anthracycline-containing regimens, specifically among those diagnosed between the ages of 66 years and 75 years. It is important to note that the 10-year survival rate was 17% to 34% lower among those diagnosed with CHF compared with those who were not. The risk of cardiovascular-related death also was 3-fold greater for patients with follicular lymphoma who were diagnosed with CHF. Anthracyclines and preexisting hypertension and diabetes were found to be the major risk factors for the development of new-onset CHF, providing evidence of the need to institute aggressive measures to manage these cardiovascular risk factors to reduce the risk of CHF among patients with follicular lymphoma. 34 
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